Home / Open for comment

FINAL RULECOMMENTS DUE DECEMBER 14, 2026

Schedules of Controlled Substances: Placement of Oveporexton in Schedule IV

Justice Department / Drug Enforcement Administration

On August 5, 2026, the United States Food and Drug Administration (FDA) approved a new drug application for Orzeyful (oveporexton) for the treatment of narcolepsy type 1 in adults. The Department of Health and Human Services (HHS) provided the Drug Enforcement Administration (DEA) with a scheduling recommendation to place oveporexton, chemically known as N-[(2S,3R)-2-[[3-(3,5- difluorophenyl)-2-fluorophenyl]methyl]-4,4-difluoro-1-(2-hydroxy-2- methylpropanoyl)pyrrolidin-3-yl]ethanesulfonamide, in schedule IV of the Controlled Substances Act (CSA). In accordance with the CSA, as amended by the Improving Regulatory Transparency for New Medical Therapies Act, DEA is hereby issuing an interim final rule placing oveporexton, including its salts, isomers and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible, in schedule IV of the CSA.

Published November 12, 2026Document 2026-23075Effective November 12, 2026

How to comment

Comments are due December 14, 2026. Submit through the link above or follow the instructions in the document's ADDRESSES section. Say who you are, how the rule affects you, and what should change, with evidence. Comments are usually public, so leave out anything private.

New to this? Start with our free public-comment guide and example, watch Rulemaking 101 or read How to Comment on Federal Rules.

From the Federal Register as of November 20, 2026. Deadlines can change; the official document governs. Not legal advice.

Know someone following this?

Send them the page so they can check the source and the deadline.